血清HS-AFP GGT-Ⅱ对肝癌患者手术预后判断的价值  

The Value of HS-AFP and GGT-Ⅱ for Judgment of the Prognosis of Patients Receiving Surgical Treatment for Hepatocellular Carcinoma

作　　者：倪润洲[1] 杨磊[1] 肖明兵[1] 李峰[1] 陆翠华[1] 朱净[1] 

机构地区：[1]南通大学附属医院消化内科,江苏省南通市226001

出　　处：《中国肿瘤临床》2007年第4期204-207,共4页Chinese Journal of Clinical Oncology

基　　金：江苏省社会发展项目(编号:BS2004528);江苏省卫生厅科技术项目基金资助(编号:H200521)

摘　　要：目的:探讨血清肝癌特异性甲胎蛋白(HS-AFP)和γ-谷氨酰转肽酶同工酶Ⅱ(GGT-Ⅱ)对原发性肝癌患者手术预后判断的临床价值。方法:对40例肝癌患者手术切除前后的血清HS-AFP、GGT-Ⅱ进行动态观察,并与患者的生存期进行对比分析。结果:40例肝癌患者术前HS-AFP﹑GGT-Ⅱ阳性率分别为57.5%和67.5%,联合检测阳性率为80.0%。术后发生复发转移者在HS-AFP和GGT-Ⅱ阳性组分别为90.9%和58.8%,而阴性组仅分别为20.7%和26.1%。术后HS-AFP和GGT-Ⅱ二者均为阳性的患者则均有复发转移。而术后二者均为阴性组患者复发转移率仅为9.5%。单因素分析显示术后HS-AFP和GGT-Ⅱ与患者预后有关。结论:术后血清HS-AFP﹑GGT-Ⅱ对肝癌患者手术后预后判断具有重要价值。Objective： To investigate the clinical value of using hepatoma-specific alpha-fetoprotein （HS-AFP） and gamma-glutamyltransferase II （GGT-II） for predicting the outcome for patients who receive surgical treatment for hepatocellular carcinoma. Methods： Observation of the dynamic state of HS-AFP and GGT-Ⅱ in 40 patients with hepatoma, before and after excision, and a comparative study of the patients＇ survival time was conducted. Results： The preoperative positive rate of HS-AFP and GGT-Ⅱ was 57.5% and 67.5%, respectively, and the positive rate of the combined detection was 80.0%. After surgery, the recurrence and distant metastasis rate in the groups with positive HS-AFP and GGT-Ⅱ was 90.9% and 58.8%, respectively, while that in the groups with negative HS-AFP and GGT-Ⅱ was 20.7% and 26.1%, respectively. Recurrence and distant metastasis occurred in all cases with positive HS-AFP and GGT-Ⅱ, whereas after surgery the cases that were negative for both HS-AFP and GGT-Ⅱ accounted for only 9.5%. Univariate analysis revealed that the presence of HS-AFP and GGT-Ⅱ after surgery was related to the prognosis. Conclusion： After surgery, both the HS-AFP and GGT-Ⅱ are very useful for predicting the outcome for patients who receive surgical treatment for hepatocellular carcinoma.

关 键 词：甲胎蛋白 异质体 γ-谷氨酰转肽酶了肝细胞肝癌 预后 

分 类 号：R735.7[医药卫生—肿瘤]